{"nctId":"NCT00700427","briefTitle":"A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","startDateStruct":{"date":"2008-06"},"conditions":["Attention Deficit Hyperactivity Disorder"],"count":2017,"armGroups":[{"label":"Atomoxetine","type":"EXPERIMENTAL","interventionNames":["Drug: atomoxetine hydrochloride"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: atomoxetine hydrochloride","Drug: Placebo"]}],"interventions":[{"name":"atomoxetine hydrochloride","otherNames":["Strattera","LY139603","atomoxetine"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults\n* Male or female\n* Must meet Attention-Deficit/Hyperactivity Disorder (ADHD) according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision™ (DSM-IV-TR™) criteria\n\nExclusion Criteria:\n\n* Comorbidity with major psychiatric disorder\n* Clinically significant depression or anxiety\n* Patients with significant medical conditions\n* Current alcohol/drugs abuse/dependence\n* Concomitant excluded medications","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Maintain a Satisfactory Response During the Double-Blind Maintenance/Randomized Withdrawal Period","description":"Conners' Adult ADHD Rating Scale-Investigator Rated:Screening Version (CAARS-Inv:SV); 30-item scale (3 subscales): inattention, hyperactivity/impulsivity (9 items each), ADHD Index (12 items). Each item is scored 0 (not at all/never) to 3 (very much/very frequently). Total ADHD symptoms score (SS)=inattention+hyperactivity/impulsivity (range:0-54). Higher score=more impairment. Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) measures participant's overall severity of ADHD symptoms and scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Maintenance of response during the randomized withdrawal phase was a reduction of ≥30% in the baseline CAARS-Inv:SV Total ADHD SS and a CGI-ADHD-S score ≤3. Participants had to continuously meet the response criteria, except for 1 excursion after assessment at Week 24 through Week 37 and 1 other excursion after assessment at Week 37 through Week 49. Excursions were not permitted at 2 consecutive visits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days Until Relapse","description":"Relapse was defined as 2 consecutive visits with a CGI-ADHD-S score ≥4 points and a return to ≥80% of participant's baseline (Visit 2) CAARS-Inv:SV Total ADHD Symptom Score (SS). If the participant showed evidence of a return of symptoms at a single visit that met severity criteria described above, and because of worsening symptoms, was unwilling to remain in the study or did not return for a second visit, the participant was also considered to have relapsed.\n\nCAARS-Inv:SV is a 30-item scale (3 subscales): Inattention, Hyperactivity/Impulsivity (9 items each), ADHD Index (12 items). Each item is scored 0 (0=not at all/never) to 3 (very much/very frequently). Total ADHD SS=inattention+hyperactivity/impulsivity (range: 0-54). Higher score=more impairment. CGI-ADHD-S measures participant's overall severity of ADHD symptoms and scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life (AAQoL) Scale From Week 24 to Week 49","description":"The AAQoL is a self-reported, 29-item scale assessing functional impairments in adults with ADHD. Each item is rated on a 5-point Likert scale; range: 1 (Not at all/ Never) to 5 (Extremely/Very Often). 5-domains of scale include: work functioning, family relationships, social functioning, activities of daily living (driving, managing finances), and psychological adaptation (life satisfaction, self-esteem). These scores are transformed to a 0-100 point scale (1=0; 2=25; 3=50; 4=75; 5=100), and then the item scores are summed and divided by item count to generate overall scores. The overall scores have the same total range of scores of 0-100, with higher scores indicating better quality of life. Least Squares (LS) Mean values were adjusted for baseline AAQoL score and Investigator/site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.12"},{"groupId":"OG001","value":"-4.0","spread":"1.10"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Conner's Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (Observer Rated [CAARS-O:SV]) Total ADHD Symptom Score From Week 24 to Week 49","description":"The CAARS-O:SV is a 30-item observer (typically a significant other or close friend) completed scale containing 3 subscales: inattention (9 items), hyperactivity/impulsivity (9 items), and ADHD Index (12 items). Each item is scored 0-3 (0=not at all/never; 1=just a little/once in a while; 2=pretty much/often; 3=very much/very frequently). Inattention and hyperactivity subscales range from 0-27; ADHD index subscale range is 0-36 with higher scores indicating more impaired participants. Total ADHD symptoms score=sum of the inattention and hyperactivity/impulsivity subscales, ranging from 0-54, with higher scores indicating more impaired participants. Least Squares (LS) Mean values adjusted for treatment, pooled Investigator, and baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.60","spread":"0.56"},{"groupId":"OG001","value":"-0.10","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.90","spread":"0.44"},{"groupId":"OG001","value":"-0.10","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.60","spread":"0.46"},{"groupId":"OG001","value":"-0.10","spread":"0.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.50","spread":"0.83"},{"groupId":"OG001","value":"-0.40","spread":"0.83"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Conner's Adult ADHD Rating Scale-Self Rated (CARRS-S:SV) Total ADHD Symptom Score From Week 24 to Week 49","description":"CAARS-S:SV is a 30-item participant completed scale containing 3 subscales: inattention (9 items), hyperactivity/impulsivity (9 items), ADHD Index (12 items). 0-3 (0=not at all/never; 1=just a little/once in a while; 2=pretty much/often; 3=very much/very frequently). Inattention and hyperactivity subscales range from 0-27; ADHD index subscale range is 0-36 with higher scores indicating more impaired participants. Total ADHD symptoms score=sum of the inattention and hyperactivity/impulsivity subscales; range: 0-54 with higher scores indicating more impaired participants. Least Squares (LS) Mean values adjusted for treatment, pooled Investigator, and baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.20","spread":"0.44"},{"groupId":"OG001","value":"0.90","spread":"0.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.90","spread":"0.33"},{"groupId":"OG001","value":"0.50","spread":"0.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.70","spread":"0.38"},{"groupId":"OG001","value":"1.20","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.60","spread":"0.65"},{"groupId":"OG001","value":"1.70","spread":"0.64"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version: Self Report (BRIEF-A:Self Report) Global Executive Composite (GEC) Index Score From Week 24 to Week 49","description":"The BRIEF-A:Self Report is a 75-item self-reported measure captures adults' views of their own executive functions/self-regulation in their everyday environment. Items include: Inhibit, Shift, Emotional Control, Self Monitor, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials. Behavior is rated on a 3-point scale: 1 (behavior is never observed) to 3 (behavior is often observed). GEC Index Score is a subscore of the 75-item BRIEF-A score, reflects overall functioning and was calculated based on 70 items. Total scores range: 70-210. Lower scores = less perceived impairment. Least Squares (LS) Mean values were adjusted for treatment, pooled Investigator, and baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.70","spread":"1.88"},{"groupId":"OG001","value":"0.90","spread":"1.81"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version:Informant Report (BRIEF-A:Informant) Global Executive Composite (GEC) Index Score From Week 24 to Week 49","description":"BRIEF-A:Informant is a 75-item third-party observer's view of the participants' executive functions/self-regulation in their everyday environment. Items include: Inhibit, Shift, Emotional Control, Self Monitor, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials. Behavior is rated on a 3-point scale: 1 (behavior is never observed) to 3 (behavior is often observed). GEC Index Score is a subscore of the 75-item BRIEF-A score, reflects overall functioning and was calculated based on 70 items. Total scores range: 70-210. Lower scores = less perceived impairment. Least Squares (LS) Mean values were adjusted for treatment, pooled Investigator, and baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.4","spread":"2.16"},{"groupId":"OG001","value":"-0.6","spread":"2.17"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Quality of Life (EuroQoL) Questionnaire-5 Dimensions (EQ-5D) Index Score From Week 24 to Week 49","description":"The EQ-5D is a Self-reported, 5-item scale to assess health utility (mobility, self-care, usual activities, pain and discomfort, and depression/anxiety). Scoring is on a 3-point scale (1=no health problems, 2=some or moderate problems, 3=major health problems). A preference value Index score is calculated using societal preference developed from a general population-based valuation studies. Index score ranges: United Kingdom (UK): -0.59 to 1.0, United States (US): -0.11 to 1.0, where 1 represents best possible health and 0 represents dead, with \\<0 interpreted as a health state \"worse than dead.\" A Quality of Life Health State Score visual analog scale (VAS) was assessed, scores range from 0 to 100. Higher scores indicate better health state. Least Square (LS) Mean values were adjusted for treatment, pooled Investigator, baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.01"},{"groupId":"OG001","value":"0.00","spread":"0.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.01"},{"groupId":"OG001","value":"0.00","spread":"0.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.60","spread":"1.21"},{"groupId":"OG001","value":"3.20","spread":"1.19"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":29,"n":2011},"commonTop":["Nausea","Headache","Dry mouth","Decreased appetite","Fatigue"]}}}